Soligenix (NASDAQ:SNGX) Downgraded by ValuEngine

Share on StockTwits

Soligenix (NASDAQ:SNGX) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Monday, November 11th, ValuEngine reports.

Separately, Maxim Group reiterated a “buy” rating and issued a $4.00 price target on shares of Soligenix in a report on Thursday, August 29th.

Shares of Soligenix stock remained flat at $$1.01 during trading on Monday. The company had a trading volume of 105,058 shares, compared to its average volume of 132,991. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.42 and a quick ratio of 1.42. Soligenix has a 1 year low of $0.65 and a 1 year high of $1.39. The stock has a market cap of $21.27 million, a PE ratio of -1.49 and a beta of 1.32. The stock has a fifty day moving average of $0.95 and a 200 day moving average of $0.93.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). Soligenix had a negative return on equity of 212.69% and a negative net margin of 193.39%. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.40 million. As a group, research analysts forecast that Soligenix will post -0.46 EPS for the current year.

A hedge fund recently raised its stake in Soligenix stock. Vanguard Group Inc. raised its holdings in Soligenix, Inc. (NASDAQ:SNGX) by 23.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 412,158 shares of the biopharmaceutical company’s stock after acquiring an additional 76,955 shares during the period. Vanguard Group Inc. owned 2.10% of Soligenix worth $293,000 at the end of the most recent reporting period. 9.89% of the stock is currently owned by hedge funds and other institutional investors.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.

Further Reading: What is the definition of a trade war?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.